These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 27502725)

  • 21. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial.
    Welt A; Marschner N; Lerchenmueller C; Decker T; Steffens CC; Koehler A; Depenbusch R; Busies S; Hegewisch-Becker S
    Breast Cancer Res Treat; 2016 Feb; 156(1):97-107. PubMed ID: 26927446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
    Miles D; Ciruelos E; Schneeweiss A; Puglisi F; Peretz-Yablonski T; Campone M; Bondarenko I; Nowecki Z; Errihani H; Paluch-Shimon S; Wardley A; Merot JL; Trask P; du Toit Y; Pena-Murillo C; Revelant V; Klingbiel D; Bachelot T;
    Ann Oncol; 2021 Oct; 32(10):1245-1255. PubMed ID: 34224826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
    Miles DW; Chan A; Dirix LY; Cortés J; Pivot X; Tomczak P; Delozier T; Sohn JH; Provencher L; Puglisi F; Harbeck N; Steger GG; Schneeweiss A; Wardley AM; Chlistalla A; Romieu G
    J Clin Oncol; 2010 Jul; 28(20):3239-47. PubMed ID: 20498403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.
    Bisagni G; Musolino A; Panebianco M; De Matteis A; Nuzzo F; Ardizzoni A; Gori S; Gamucci T; Passalacqua R; Gnoni R; Moretti G; Boni C
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):1051-7. PubMed ID: 23377310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.
    Miles D; Cameron D; Bondarenko I; Manzyuk L; Alcedo JC; Lopez RI; Im SA; Canon JL; Shparyk Y; Yardley DA; Masuda N; Ro J; Denduluri N; Hubeaux S; Quah C; Bais C; O'Shaughnessy J
    Eur J Cancer; 2017 Jan; 70():146-155. PubMed ID: 27817944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
    Fang Y; Qu X; Cheng B; Chen Y; Wang Z; Chen F; Xiong B
    Tumour Biol; 2015 Mar; 36(3):1933-41. PubMed ID: 25387808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses.
    Brodowicz T; Lang I; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Petruzelka L; Eniu A; Anghel R; Koynov K; Vrbanec D; Pienkowski T; Melichar B; Spanik S; Ahlers S; Messinger D; Inbar MJ; Zielinski C
    Br J Cancer; 2014 Nov; 111(11):2051-7. PubMed ID: 25268370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
    Tripathy D; Kaufman PA; Brufsky AM; Mayer M; Yood MU; Yoo B; Quah C; Yardley D; Rugo HS
    Oncologist; 2013; 18(5):501-10. PubMed ID: 23652380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer.
    Borson R; Harker G; Reeves J; Beck T; Hager S; Horvath W; Jones M; Tillinghast G; Arrowsmith E; Harrer G; Kudrik FJ; Malamud SC; Bromund J; Zeigler H; Tai DF; Kornberg LJ; Obasaju C; Orlando M; Yardley DA
    Clin Breast Cancer; 2012 Oct; 12(5):322-30. PubMed ID: 23040000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial.
    Brufsky A; Valero V; Tiangco B; Dakhil S; Brize A; Rugo HS; Rivera R; Duenne A; Bousfoul N; Yardley DA
    Breast Cancer Res Treat; 2012 Jun; 133(3):1067-75. PubMed ID: 22415477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.
    Yardley DA; Bosserman LD; O'Shaughnessy JA; Harwin WN; Morgan SK; Priego VM; Peacock NW; Bass JD; Burris HA; Hainsworth JD
    Breast Cancer Res Treat; 2015 Nov; 154(1):89-97. PubMed ID: 26456573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study.
    Yamamoto Y; Yamashiro H; Toh U; Kondo N; Nakamura R; Kashiwaba M; Takahashi M; Tsugawa K; Ishikawa T; Nakayama T; Ohtani S; Takano T; Fujisawa T; Toyama T; Kawaguchi H; Mashino K; Tanino Y; Morita S; Toi M; Ohno S
    Breast Cancer; 2021 Jan; 28(1):145-160. PubMed ID: 32715420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.
    Brufsky A; Hoelzer K; Beck T; Whorf R; Keaton M; Nadella P; Krill-Jackson E; Kroener J; Middleman E; Frontiera M; Paul D; Panella T; Bromund J; Zhao L; Orlando M; Tai F; Marciniak MD; Obasaju C; Hainsworth J
    Clin Breast Cancer; 2011 Aug; 11(4):211-20. PubMed ID: 21723792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
    Martín M; Loibl S; Hyslop T; De la Haba-Rodríguez J; Aktas B; Cirrincione CT; Mehta K; Barry WT; Morales S; Carey LA; Garcia-Saenz JA; Partridge A; Martinez-Jañez N; Hahn O; Winer E; Guerrero-Zotano A; Hudis C; Casas M; Rodriguez-Martin C; Furlanetto J; Carrasco E; Dickler MN; ; ;
    Eur J Cancer; 2019 Aug; 117():91-98. PubMed ID: 31276981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.
    Gampenrieder SP; Romeder F; Muß C; Pircher M; Ressler S; Rinnerthaler G; Bartsch R; Sattlberger C; Mlineritsch B; Greil R
    Anticancer Res; 2014 Jan; 34(1):227-33. PubMed ID: 24403467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients.
    Cascinu S; Rosati G; Nasti G; Lonardi S; Zaniboni A; Marchetti P; Leone F; Bilancia D; Iaffaioli RV; Zagonel V; Giordano M; Corsi DC; Ferraú F; Labianca R; Ronzoni M; Scartozzi M; Galli F;
    Eur J Cancer; 2017 Sep; 83():106-115. PubMed ID: 28735067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study.
    Boulaamane L; Boutayeb S; Errihani H
    BMC Res Notes; 2012 Mar; 5():162. PubMed ID: 22439740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer].
    Ma F; Xu BH; Li HH; Li Q; Zhang P; Yuan P; Wang JY; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):521-4. PubMed ID: 24257305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.
    Zielinski C; Lang I; Beslija S; Kahan Z; Inbar MJ; Stemmer SM; Anghel R; Vrbanec D; Messinger D; Brodowicz T
    Br J Cancer; 2016 Jan; 114(2):163-70. PubMed ID: 26657657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO.
    Pivot X; Schneeweiss A; Verma S; Thomssen C; Passos-Coelho JL; Benedetti G; Ciruelos E; von Moos R; Chang HT; Duenne AA; Miles DW
    Eur J Cancer; 2011 Nov; 47(16):2387-95. PubMed ID: 21757334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.